Chronic myeloid leukemia (CML) is caused by the Philadelphia (Ph+) chromosome carrying
the BCR-ABL oncogene, a constitutively active tyrosine kinase. The discovery of imatinib …

Abstract Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm primarily due to
the presence of the BCR-ABL fusion gene that produces the constitutively active protein …

Imatinib, a small-molecule ABL kinase inhibitor, is a highly effective therapy for early-phase
chronic myeloid leukaemia (CML), which has constitutively active ABL kinase activity owing …

The deregulated, oncogenic tyrosine kinase Bcr-Abl causes chronic myeloid leukemia
(CML). Imatinib mesylate (Gleevec, STI571), a Bcr-Abl kinase inhibitor, selectively inhibits …

Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic
myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to …

Imatinib mesylate, a selective inhibitor of the Abl tyrosine kinase, is effective as a single-
agent therapy for chronic myelogenous leukemia. However, resistance has been reported …

Imatinib is a selective breakpoint cluster region–Abelson (BCR-ABL) tyrosine kinase
inhibitor (TKI) that has significantly improved the prognosis of patients with chronic myeloid …

Chronic myelogenous leukemia (CML) arises from the constitutive activity of the BCR-ABL1
oncoprotein. Tyrosine kinase inhibitors (TKIs) that target the ATP-binding site have …

In chronic myelogenous leukaemia (CML), a reciprocal translocation between chromosomes
9 and 22 results in a gene encoding BCR–ABL, a fused deregulated kinase that stimulates …

Imatinib was developed as the first molecularly targeted therapy to specifically inhibit the
BCR-ABL kinase in Philadelphia chromosome (Ph)-positive chronic myeloid leukemia …